Premium
Long‐term follow up of autologous serum treatment for recurrent corneal erosions
Author(s) -
Ziakas Nikolaos G,
Boboridis Konstantinos G,
Terzidou Chryssa,
Naoumidi Tatiana L,
Mikropoulos Dimitris,
Georgiadou Eirini N,
Georgiadis Nick S
Publication year - 2010
Publication title -
clinical and experimental ophthalmology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.3
H-Index - 74
eISSN - 1442-9071
pISSN - 1442-6404
DOI - 10.1111/j.1442-9071.2010.02304.x
Subject(s) - medicine , surgery , visual acuity , prospective cohort study , ophthalmology
A bstract Purpose: The aim of the study was to evaluate long‐term results of autologous serum treatment for recurrent corneal erosions. Methods: In this prospective single‐centre study, 33 eyes of 33 patients (21 male and 12 female) were treated with autologous serum eye drops for recurrent corneal erosions. Mean age of the patients was 49.3 ± 9.8 standard deviation (range 24–73) years. All subjects had failed to respond to other treatments. Autologous serum drops were administered for a 6‐month period: six times daily for the first 3 months and four times daily for the remaining 3 months. Detailed informed consent was obtained from the entire patient group before the study. Results: The mean follow‐up period was 30 ± 6.3 standard deviation (range 12–48) months. None of the patients experienced a recurrence while under treatment. Twenty‐eight patients (85%) had complete healing of erosions with no relapses of the disease over the whole follow‐up period. Five patients (15%) presented a single recurrence 3–12 months after the end of the treatment. No sight‐threatening complications were reported over the follow up. There was no statistically significant difference in the best spectacle‐corrected visual acuity values ( t stat = 2.1, F = 0.096, degree of freedom = 40 166, P < 0.41) or in the intraocular pressure measurements ( P < 0.38) between the pre‐ and post‐treatment patient groups. Conclusions: Autologous serum drops proved to be a safe and efficient treatment modality for patients with recurrent corneal erosion syndrome as observed through a long‐term follow up.